Is Progesterone Used in Gender-Affirming Hormone Therapy? A Look at Current Evidence
The short answer is yes — some providers prescribe progesterone as part of feminizing hormone therapy, but it is not a standard component of the regimen, and the evidence behind it is thinner than most online discussions let on. Below, I walk through the evidence as it stands and how I approach progesterone with my own patients.
I get asked about progesterone a lot in my office. I usually start by pointing out that most of what's out there is anecdotal, and it's only recently that we've had any studies looking at whether it does what people say it does in gender-affirming hormone therapy. The most comprehensive safety data we have on progesterone didn't include transgender and gender diverse people at all — it came from hormone therapy research in cisgender women before, during, and after menopause. But the sheer amount of anecdotal experience with bioidentical progesterone is compelling too.
Why People Ask About Progesterone
Progesterone is one of the two major sex hormones the ovaries produce, alongside estrogen. Standard feminizing regimens replace estrogen and suppress testosterone, but they leave progesterone out. For a lot of people that omission feels like an incomplete picture, and the reasoning is intuitive: if the goal is a hormonal profile closer to that of a cisgender woman, why skip a hormone cisgender women make?
Online communities are full of reports that progesterone improved breast development, mood, libido, or sleep. Those reports are worth taking seriously, even if, as you'll see below, they're hard to confirm with current available published data.
People don't only ask whether progesterone belongs in their feminizing regimen — they also ask how to take it. There are sources online and in the community that recommend very specific ways of administering it, including pricking the capsule and using it rectally rather than swallowing it. I can't confirm that any of those are the most effective way to take the medication... What I can say is that many of my patients have found real benefit to their mood, sleep, or libido on progesterone.
The other question I hear constantly is about timing: when should I start? At initiation? Six months in? Nine months? At one or even two years? What produces the best results with the fewest side effects?
Progesterone and Progestins Are Not the Same Thing
Most articles blur this distinction, and it matters for everything that follows.
Micronized progesterone (brand name Prometrium, usually dosed 100–200 mg at night) is bioidentical — structurally identical to what the ovaries produce.(1) Progestins are synthetic compounds that act on progesterone receptors but differ chemically; medroxyprogesterone acetate (Provera) is the common example.(1) They're not interchangeable. Their side-effect profiles differ, and much of the older safety data cited against "progesterone" studied a synthetic progestin, not the bioidentical form.
When you see the word "progesterone" in a study or a forum thread, it's worth checking which molecule is meant.
Know the difference
Progesterone Is Not the Same as a Progestin
Two different molecules that often get grouped under one word.
Micronized Progesterone
e.g., Prometrium
- Structure
- Identical to the progesterone the body makes.
- In feminizing therapy
- The form most patients use, typically 100–200 mg at night.
- Risk data
- Much of the older “progesterone risk” data studied the synthetic form, not this one.
Progestins
e.g., medroxyprogesterone acetate (Provera)
- Structure
- Bind progesterone receptors, but are chemically different.
- In feminizing therapy
- Sometimes used to help suppress testosterone.
- Risk data
- The source of most older “progesterone risk” findings.
When you read about “progesterone,” check which one is meant.
What the Major Guidelines Say
No professional society has issued a strong recommendation either for or against progesterone in feminizing therapy. The positions range from cautious to permissive.
The WPATH Standards of Care, 8th edition commissioned a systematic review for this question and could not find enough data to recommend any progestin; the reported benefits remain anecdotal, and the review noted that existing data suggest possible harm from extended progestin exposure.(2) The Endocrine Society Clinical Practice Guideline does not include progesterone as a standard feminizing agent and states plainly that there have been no well-designed studies of progestogens in feminizing regimens — the question is open.(3)
A 2021 European Journal of Endocrinology review was more direct, stating that natural progesterone is not recommended as part of gender-affirming hormone therapy given how little is known about the risk–benefit balance.(4) The American College of Obstetricians and Gynecologists took a more permissive line, noting that progestins may increase breast development and improve libido and mood in some patients.(5)
As an internist, my job is to lay out the available data and help reduce the potential harms of whatever we decide to pursue. When the data conflicts, the next best step is to put as much of it on the table as I can, so the patient and I can reach a decision together through informed consent.
What the Studies Are Currently Saying
The published data is mostly retrospective and survey-based. I haven’t seen a randomized controlled trial that has been done yet. With that ceiling in mind, here's what exists.
Bahr et al. (2023) compared feminizing therapy with and without progesterone in a retrospective cohort of 88 patients. The progesterone group reported significantly greater satisfaction with breast development at 6 months (53.8% vs. 19.6%) and 9 months (71.4% vs. 20.8%), and better provider-documented mental health at 6 months (70.6% vs. 28.2%).(6) Differences in testosterone suppression, libido, and weight were not statistically significant.(6)
Jain et al. (2019) looked at medroxyprogesterone acetate across 290 follow-up visits. The MPA group had markedly lower testosterone (79 vs. 215 ng/dL) with minimal side effects and unchanged estradiol.(7) Among 39 patients on MPA, 26 reported improved breast development and 11 reported decreased facial hair.(7)
Chang et al. (2025) is the largest survey to date, with 543 respondents. Among 310 progestogen users, oral micronized progesterone was the most common formulation (58.4%), and most users perceived improvement in breast development (79.6%) and sense of femininity (81.3%).(8) Common side effects were breast pain (28.7%) and mood fluctuation (21.9%). The survey also recorded thromboembolic events — 6 DVTs, 4 PEs, and 4 strokes — though a survey design cannot establish whether progesterone caused them.(8)
The pattern is consistent: patients report benefits, especially for breast development and mood, and no study has been built to confirm those reports or rule out the risks. Satisfaction surveys and chart reviews can't tell a real hormonal effect apart from the expectation of one, or from the changes that come with more time on estrogen.
What the research shows
The Evidence on Progesterone in Feminizing Therapy
Satisfaction with breast development at 9 months: 71% vs 21%, with progesterone versus without.
Lower testosterone on the progestin MPA: 79 vs 215 ng/dL.
79% of progestogen users felt their breast development improved.
Patients consistently report benefits, especially for breast development and mood. Reported downsides included breast tenderness, mood changes, and rare clotting events whose cause could not be established. The data isn’t yet strong enough to confirm any of it.
The Argument for Adding Progesterone
The strongest case for progesterone is anecdotal and theoretical. In an influential 2019 commentary, Prior argued that progesterone should be added to feminizing therapy by extrapolation from cisgender female physiology, proposing benefits including more complete breast maturation to Tanner stages 4 and 5, increased bone formation, better sleep, and possible cardiovascular benefit.(9)
It's a serious argument and worth reading. But by Prior's own framing it's an extrapolation: the direct evidence in transgender women for these specific benefits doesn't exist yet. A physiological rationale is a good reason to study something. While it isn't the same as proof that it works, neither is it a refutation that progesterone doesn’t cause the intended effects.
Risks and Safety
The risks are real but not as settled as either side tends to claim.
Documented adverse effects of progestins include weight gain, mood changes including depression, and shifts in lipids.(2,10) For progesterone, some patients also experience sedation, which is part of why micronized progesterone is dosed at night — and which some people count as a benefit for sleep rather than a side effect.
The frequently cited cardiovascular and breast cancer concerns come largely from the Women's Health Initiative, which studied older cisgender women taking a synthetic progestin alongside conjugated equine estrogen.(2) That population differs from a younger transgender woman on bioidentical estradiol, so the WHI findings do not transfer cleanly.(10) A 2023 review found no clearly demonstrated increase in cardiovascular disease or breast cancer specifically in the transgender population, and a 2024 narrative review concluded progesterone may be beneficial without significant adverse effects — while stressing that randomized trials are urgently needed.(10,11)
"No demonstrated increase in risk" is not the same as "demonstrated safe" — it mostly reflects how little research has been done.
How I Think About Progesterone With My Patients
In my practice, I do prescribe progesterone fairly often. But it's a shared decision, and I talk it through with every patient on feminizing hormone therapy. Because there's so much anecdotal experience pointing to benefits for secondary sex development — breast contouring and fullness in particular — it can be an important part of many people's regimens.
The conversation I have before anyone starts progesterone begins with how long we'll use it. My own approach is conservative: I generally cap combined estrogen-and-progesterone use at about two years. This isn't a formal published guideline — it's a practice I carried over from endocrinologists I trained under, meant to limit prolonged hormonal stimulation of hormone-sensitive tissue. The caution comes from breast cancer data in cisgender women, though that signal came mostly from synthetic progestins given continuously, not from natural progesterone.(12) There's a more general point here too: breast cancer risk tracks with breast tissue itself. Anyone with developed breast tissue carries more baseline risk than someone with little or none — it's part of why someone after a mastectomy, or most cis men, sits lower. Feminizing therapy is partly about developing that tissue, so some of that baseline comes with the territory. At the two-year mark I revisit all of this with the patient, and we decide together whether to keep going or stop.
The next thing we talk about is timing. I'm usually in the camp of starting at least six months after estrogen, because I want breast tissue to develop first so the progesterone has something to act on. Some people have told me they've heard early progesterone can blunt breast bud development — I haven't seen conclusive data on that either way.
One real difference from estrogen is monitoring: we don't measure progesterone levels, because we don't have established target ranges for it. In the body, progesterone is produced cyclically, tied to the menstrual cycle. So some patients choose to cycle it — two weeks on, taken daily, then two weeks off — which can be tailored to the individual. Cycling may also lower progesterone's influence on breast cancer risk: natural progesterone given in cyclic rather than continuous regimens does not appear to raise that risk, and the withdrawal between cycles may be part of why.(12)
The last thing I'll say is about time itself. I built my appointments to be long enough that we can sit with this kind of information instead of rushing through it — and when the evidence and the guidelines don't line up, that time matters even more. It's what lets us weigh the real risks and benefits so you can make the best decision for you.
The Bottom Line: Is Progesterone Used in Gender-Affirming Hormone Therapy?
Yes, in practice — progesterone use in feminizing therapy is common, even though no guideline strongly endorses it and no randomized trial supports it.
Micronized progesterone and synthetic progestins are different drugs with different risk profiles; the distinction matters.
Retrospective and survey data suggest patient-perceived benefits for breast development and mood, with no clearly demonstrated increase in serious harm — but the evidence is not strong enough for a firm conclusion either way.
It's worth raising with your provider, and reasonable to try with monitoring — just not something the current evidence lets anyone promise.
References
UCSF Gender Affirming Health Program. Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People. Deutsch MB, ed. 2nd ed. University of California, San Francisco; 2016.
Coleman E, Radix AE, Bouman WP, et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. Int J Transgend Health. 2022;23(suppl 1):S1-S259.
Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017.
Glintborg D, T'Sjoen G, Ravn P, Andersen MS. MANAGEMENT OF ENDOCRINE DISEASE: Optimal Feminizing Hormone Treatment in Transgender People. Eur J Endocrinol. 2021. PMID: 34081614.
Committee on Gynecologic Practice and Committee on Health Care for Underserved Women. Health Care for Transgender and Gender Diverse Individuals: ACOG Committee Opinion, Number 823. Obstet Gynecol. 2021.
Bahr C, Ewald J, Dragovich R, Gothard MD. Effects of Progesterone on Gender Affirmation Outcomes as Part of Feminizing Hormone Therapy. J Am Pharm Assoc (2003). 2023. PMID: 37549733.
Jain J, Kwan D, Forcier M. Medroxyprogesterone Acetate in Gender-Affirming Therapy for Transwomen: Results From a Retrospective Study. J Clin Endocrinol Metab. 2019. PMID: 31127826.
Chang JJ, Tran NK, Flentje A, et al. Progestogen Experience Among Transgender Women and Gender Diverse Adults Assigned Male at Birth in the United States. Endocr Pract. 2025. PMID: 40633693.
Prior JC. Progesterone Is Important for Transgender Women's Therapy — Applying Evidence for the Benefits of Progesterone in Ciswomen. J Clin Endocrinol Metab. 2019. PMID: 30608551.
Sudhakar D, Huang Z, Zietkowski M, Powell N, Fisher AR. Feminizing Gender-Affirming Hormone Therapy for the Transgender and Gender Diverse Population: An Overview of Treatment Modality, Monitoring, and Risks. Neurourol Urodyn. 2023.
Szymczyk S, Mączka K, Mądrzak L, Grymowicz M, Smolarczyk R. The Potential Health Risks and Benefits of Progesterone in the Transgender Woman Population — A Narrative Review. J Clin Med. 2024. PMID: 39597939.
Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F. Progestins and Progesterone in Hormone Replacement Therapy and the Risk of Breast Cancer. J Steroid Biochem Mol Biol. 2005;96(2):95-108. PMID: 15908197.
